CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 428 · Search date 2026-07-17 · Methodology v0.6

LD100 lemon balm-dandelion complex,
does it really help with Liver health and improvement in liver enzymes?

30-Second Summary
C
Evidence Grade C · 48 · Safety caution
A liver-enzyme signal exists for the specific LD100 product, but it is not independently replicated evidence of improved liver disease
What the
research shows
A Korean regulatory review reports that ALT and GGT decreased versus control in a 12-week human study of 90 adults taking 500 mg/day of LD100. The disclosed evidence, however, centers on one study of a specific 2:1 branded complex and surrogate liver-enzyme endpoints; no independent replication or clinical liver outcome was identified. The grade is C.
What the
ads claim
Claims such as 'newer and better than milk thistle,' protection from alcoholic liver injury, or liver-cell regeneration exceed the trial. The disclosed human evidence concerns ALT and GGT changes with the specific LD100 complex and cannot be attributed to lemon balm tea or dandelion alone.
*

Useful facts when choosing a product

  • The recognized daily intake is 500 mg/day as LD100.
  • The ingredient is a specific complex of lemon balm leaf and dandelion leaf extract powders, standardized to rosmarinic acid and chicoric acid.
  • Tablets, capsules, and liquid health-functional foods containing LD100 are sold in Korea, sometimes with B vitamins and other ingredients.
  • Official precautions advise infants, children, adolescents, pregnant or breastfeeding people, and those planning pregnancy not to use it; users of sleep aids, thyroid hormones, or central nervous system depressants should consult a professional.
Gap Measurement · Verdict 428 · C 48
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Korean Ministry of Food and Drug Safety consumer report summarizes a study in 90 adults aged 19-70 years with ALT of 35-105 IU/L. Participants consumed LD100 at 500 mg/day for 12 weeks, and ALT and GGT decreased significantly versus control. The report describes a mixture of lemon balm leaf and dandelion leaf extract powders standardized to rosmarinic acid and chicoric acid. A full peer-reviewed paper, prospective registration, detailed statistical report, and independent replication were not identified in the public search.

02

Why this is classified as C (48)

ALT and GGT surrogate markers improved in one manufacturer-submitted study of a branded ingredient, but there is no independent replication, fully public paper, or clinical liver outcome. The branded-product cap yields C with 48 points.

Counterpoint. The liver-enzyme signal comes from an actual controlled 90-person human study, so the ingredient is not treated as preclinical-only.

Rejudgment record. New verdict — Positive ALT and GGT surrogate markers in a single manufacturer-submitted branded-product study, with no independent replication or clinical outcome

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improvement in ALT and GGTCPositive in one controlled 90-person branded-product study, but based on manufacturer-submitted surrogate-marker evidence.
Improvement in liver health or clinical liver outcomes?No public human evidence was identified for disease progression, symptoms, hospitalization, or histologic improvement.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Regulatory summary of a controlled human application study90Submitted by the ingredient applicantALT and GGTALT and GGT decreased significantly versus control after 500 mg/day for 12 weeks.Key
Study 2Animal liver-injury studiesSubmitted by the ingredient applicantALT, AST, 4-HNE, TNF-alpha, SOD, and CATChanges in enzyme, oxidative, and inflammatory markers in carbon-tetrachloride or ethanol injury models.Mechanistic
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-17).

Reference 1
checked
Reference 2
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

LD100 lemon balm-dandelion complex x liver health and liver enzymes Evidence Grade C card
[Chamgap] LD100 lemon balm-dandelion complex x liver health and liver enzymes — Evidence Grade C·48. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/ld100-lemon-balm-dandelion-liver/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.